NEW YORK (360Dx) – Sciex is counting on its newly announced joint venture with Zhejiang Dian Diagnostics to speed its penetration of the Chinese clinical mass spec market, which a company official said is "set to explode."
Factors like the country's interest in multiplexed diagnostic panels and wellness monitoring have its clinical mass spec space "poised for huge growth," said Aaron Hudson, VP and general manager of Sciex's diagnostics division.